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Controlled human exposure studies have
shown acute dose–effect relations for exposure
to volatile organic compounds (VOCs) with
respect to odor and irritative symptoms
(Mölhave et al. 1986, 1991). Also, histamine
release from human bronchoalveolar cells has
been shown after exposure to microbial VOCs
(MVOCs) from indoor mold (Larsen et al.
1998). Up to 300 different compounds,
including 3-methylfuran (3-MF), can be
detected in indoor air (Berglund and
Johansson 1996).
3-MF is formed by a broad spectrum of
fungi (Börjesson et al. 1992) and can be used as
a marker for the active growth of micro-
organisms in water-damaged buildings (Wessen
and Schoeps 1996). The substance has a char-
acteristic fungal smell. It is biologically active
and binds covalently to tissue macromolecules
after metabolic oxidation. In one study,
increased indoor levels of 3-MF were signiﬁ-
cantly related to symptoms of airway obstruc-
tion (Smedje et al. 1996). Thus, 3-MF may be
suspected to contribute to the exacerbation of
pulmonary diseases (Boyd et al. 1978).
The aim of the present study was to assess
the acute effects of 3-MF on the eyes, nose,
and airways via a battery of physiologic and
biochemical tests (Ernstgård et al. 2002). The
choice of 3-MF was based on its chemical
properties and previous epidemiologic associa-
tions with respiratory symptoms (Smedje et al.
1996).
Materials and Methods
Subjects and chamber exposures. The study
group consisted of 30 healthy volunteers
(14 females) 20–54 years of age (mean ± SD,
33 ± 9 years) that were medically examined
before the ﬁrst exposure. Atopy was tested by
laboratory veriﬁed IgE antibodies to common
Swedish allergens: cat, dog, horse, birch
pollen, timothy, mugwort, Cladosporium
herbarum, Dermatophagoides pteronyssinus, and
Dermatophagoides farinae (Phadiatop test;
Pharmacia Diagnostics, Uppsala, Sweden);
43% of the volunteers had laboratory veriﬁed
atopy. The volunteers were informed orally
and in writing about the design of the study,
possible hazards, and their freedom to discon-
tinue participation at any time. The study was
approved by the Regional Ethical Committee
at the Karolinska Institute, Solna, Sweden,
and written consent was obtained from the
participants.
The subjects were exposed to clean air and
3-MF (1 mg/m3) in random order. Each expo-
sure session lasted for 2 hr. Exposures were
conducted during resting conditions with the
subjects seated. Up to ﬁve subjects at a time
were exposed. Exposures were performed from
December through February to minimize pos-
sible interference with pollen exposure, with a
minimum period of 2 weeks between the two
exposure conditions. The exposures were car-
ried out in a 20-m3 dynamic exposure cham-
ber with 18–20 air changes per hour. The
temperature and the humidity in the chamber
were set to 24°C and 30%, respectively.
Temperature and humidity were continuously
recorded (Vaisala HMP 36, Vaisala, Helsinki,
Finland) and logged (Squirrel Meter Logger
1200 Series, Grant Instruments, Cambridge,
UK). 3-MF vapor was generated by injecting
liquid solvent into inlet air by means of a high-
pressure piston pump (Gilson 302, Gilson,
Villiers-le-bel, France). The inlet air was dis-
persed throughout the entire chamber ceiling.
Air was sampled from the upper central
part of the exposure chamber to monitor the
concentration of the compound during expo-
sures. The air samples were transferred through
a Teﬂon-coated tube to a gas chromatograph
by means of a pump (DDA-P101-BN, Gast,
Benton Harbor, MI, USA). The gas chro-
matograph (Auto system; Perkin Elmer,
Buckinghamshire, UK) was equipped with a
wide-bore capillary column (CP-sil 8, 10 m,
0.53 mm inner diameter, 2 µm; Chrompack,
Middleburg, the Netherlands) and a ﬂame ion-
ization detector. Helium was used as a carrier
gas; the temperatures of the oven and the
detector were 55°C and 250°C, respectively.
Symptom questionnaire. At six different
times, subjects were asked to fill out a ques-
tionnaire with 10 questions related to smell,
irritative symptoms (of the eyes, nose, and
throat), dyspnea, headache, fatigue, dizziness,
nausea, and intoxication. Answers were given
by marking along a 100-mm visual analogue
scale graded from “not at all” (0 mm) to
“almost unbearable” (100 mm). The question-
naire was elaborated for vapor exposure and
has been used in several inhalation studies
(Ernstgård et al. 2002; Falk et al. 1991; Iregren
et al. 1993; Nihlen et al. 1998).
Blinking frequency. Blinking of the left
eye was recorded by electromyography
(EMG) using three skin electrodes, two on the
orbicularis oculi muscle and one reference
electrode on the cheekbone. The EMG signal
was ampliﬁed and transferred via telemetry to
a personal computer. We used a software pro-
gram in C++ to identify the characteristic
EMG signal patterns. We identiﬁed blinks by
comparison against nine conditions related to
the size, shape, and appearance of the pattern
(Ernstgård et al. 2002).
Tear ﬁlm break-up time. Precorneal tear
film stability was assessed by measuring the
tear film break-up time by scanning the
precorneal tear film with a biomicroscope
(Topcon SL1E; Topcon, Tokyo, Japan). The
Address correspondence to R. Wålinder, Department
of Occupational and Environmental Medicine,
University Hospital, 751 85 Uppsala, Sweden.
Telephone: 46-18-6113641. Fax: 46-19-519978.
E-mail: robert.walinder@medsci.uu.se
This study was supported by grants from the
Swedish Council for Worklife Research and the
Swedish Foundation for Health Care Sciences and
Allergy Research.
The authors declare they have no competing
ﬁnancial interests.
Received 11 April 2005; accepted 9 August 2005.
Acute Effects of a Fungal Volatile Compound
Robert Wålinder,1 Lena Ernstgård,2 Gunnar Johanson,2 Dan Norbäck,1 Per Venge,3 and Gunilla Wieslander1
1Department of Medical Sciences/Occupational and Environmental Medicine, University Hospital, Uppsala, Sweden; 2Division of Work
Environment Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 3Department of Medical
Sciences/Clinical Chemistry and Asthma Research Center, University Hospital, Uppsala, Sweden
OBJECTIVE: 3-Methylfuran (3-MF) is a common fungal volatile product with active biologic proper-
ties, and previous studies have indicated a contribution to airway disease. The aim of the present
study was to assess the acute health effects of this compound in humans.
DESIGN: Acute effects were assessed via chamber exposure to (1 mg/m3) 3-MF.
PARTICIPANTS AND MEASUREMENTS: Twenty-nine volunteers provided symptom reports, ocular
electromyograms, measurement of eye tear film break-up time, vital staining of the eye, nasal
lavage, acoustic rhinometry, transfer tests, and dynamic spirometry.
RESULTS: No subjective ratings were signiﬁcantly increased during exposure. Blinking frequency
and the lavage biomarkers myeloperoxidase and lysozyme were signiﬁcantly increased, and forced
vital capacity was signiﬁcantly decreased during exposure to 3-MF compared with air control.
CONCLUSIONS AND RELEVANCE TO CLINICAL PRACTICE: Acute effects in the eyes, nose, and airways
were detected and might be the result of the biologically active properties of 3-MF. Thus, 3-MF
may contribute to building-related illness.
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blink until a rupture in the precorneal film
was observed. We also estimated tear ﬁlm sta-
bility by recording the self-reported tear ﬁlm
break-up time. The subjects were asked to
keep their eyes open, and the time was
recorded until they felt an urge to blink,
assuming that this feeling was the appearance
of a dry spot on the cornea (Wieslander et al.
1999). Measurements of break-up time were
performed on three occasions in each eye:
before entering the chamber, at the end of
exposure, and 4 hr after exposure.
Vital staining of the eye. We assessed
epithelial damage to the cornea and conjunctiva
using a semiquantitative method. We instilled
4 µL of a dye, lissamine green (1% in physio-
logic saline solution), into the lower conjuncti-
val sac. After 1 min, the cornea and conjunctiva
were examined by a binocular microscope with
a slit lamp (Topcon SL1E), and each eye was
given a score of 0–9 (Norn 1991). Vital stain-
ing was performed once, 4 hr after exposure.
Nasal lavage. We measured inﬂammatory
markers in nasal lavage samples before, directly
after, and at 2 hr postexposure. Lavage of the
nasal mucosa was collected with a 20-mL plas-
tic syringe attached to a nose olive (Wålinder
1999). The analyses included myeloperoxidase
(MPO), eosinophil cationic protein (ECP),
lysozyme, and albumin and were carried out at
the Department of Clinical Chemistry,
University Hospital, Uppsala, Sweden. The
chemical analysis of lavage biomarkers has been
described in detail elsewhere (Wålinder 1999).
Transfer test. We determined the diffusion
capacity of carbon monoxide (DLCO) using a
single-breath technique (transfer test; PK
Morgan Ltd., Chatham, Kent, UK) (Cotes
et al. 1997; Forster et al. 1954). DLCO was
measured for each subject before entering the
exposure chamber and 20 min after leaving
the exposure chamber.
Dynamic spirometry. Dynamic spirometric
measurements were performed for each subject
before entering the exposure chamber, imme-
diately after leaving it, and 2 hr after leaving
the chamber. Spirometric tests included vital
capacity (VC), forced vital capacity (FVC),
forced expiratory volume in 1 sec (FEV1), peak
expiratory flow (PEF), and forced expiratory
flow (FEF) in the middle half of FVC [FEF
25, 50, 75, the expiratory flows after one-
fourth, one-half, and three-fourths, respec-
tively, of the vital capacity has been expired
(after a full inspiration)]. The tests were per-
formed by spirometry (Vitalograph 2120 and
Spirotrac 3 software for PC, version 2.0;
Vitalograph, Buckingham, UK) according to
the guidelines prescribed by the American
Thoracic Society (1995).
Acoustic rhinometry. We assessed nasal
patency using acoustic rhinometry. The nasal
volume (from the nostril and 7 cm into the
nasal cavity) and the minimal cross-section area
were determined as an average of three mea-
surements in each nostril. We performed the
rhinometric measurements for each subject at
three occasions during the exposure day: before
entering the chamber, immediately after leav-
ing it, and 2 hr after leaving it. Data on the
nasal volumes and areas are presented as the
sum of the right and the left side. The rhi-
nometer, using a single-click signal of audible
frequencies with the Nasal Area-Distance
Acquisition Program, version 1.0 (University
of Aarhus, Aarhus, Denmark), has previously
been described by Hilberg et al. (1989).
Statistical methods. We compared the dif-
ferences before and after exposure to 3-MF
and air control using t-tests for paired samples
for rhinometric and spirometric changes and
Wilcoxon matched pairs tests for the non-
normally distributed lavage data. We used
repeated-measures analysis of variance
(ANOVA) for subjective ratings and the
Wålinder et al.
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Figure 1. Subjective ratings (median with interquartile range, total range 0–100 mm) of 10 symptoms at six
times: just before entering the chamber; at 3, 60, and 118 min of exposure; and at 15 and 200 min after expo-
sure. Discomfort in the eyes (A), nose (B), and throat or airways (C); breathing difficulty (D); odor (E);
headache (F); fatigue (G); nausea (H); dizziness (I); and feeling of intoxication (J).blinking frequency series (Statistica for
Windows, version 7.0; StatSoft Inc., Tulsa,
OK, USA). Two-tailed tests and a 5% level of
signiﬁcance were applied when applicable.
Results
Suspected adverse reaction. We removed one
subject from the exposure series because of a
two-phased pulmonary reaction to 3-MF.
During the last 30 min of exposure, the subject
suffered from moderate airway distress com-
bined with acute airway obstruction. The PEF
fell from 320 L/min before exposure to
170 L/min directly after. The acute dyspnea
cleared up quickly, and by 3 hr after exposure,
the PEF was 350 L/min. Three days after
exposure, the subject had an onset of severe
chest tightness, together with chills, fatigue,
cough, and fever around 39°C. One week after
exposure, the subject suffered from leukopenia,
and obstructive symptoms remained for about
a month. The subject’s chest X ray was normal,
and no elevated titers for influenza virus A
and B were found. Titers for total IgE and a
mold-antigen panel were high. We reported
the suspected adverse effect to the Regional
Ethical Committee.
Symptom ratings. The symptom ratings
were not different during exposure to 3-MF
compared with clean air (Figure 1). An imme-
diate weak odor detection of 3-MF could be
seen among some of the subjects, but not all
(Figure E). This suggests that the exposure
level was near the odor threshold and that
adaptation occurred.
Eye measurements. The blinking fre-
quency during 3-MF exposure was signifi-
cantly higher than during clean air exposure
(Figure 2, Table 1). The vital staining scores
of epithelial eye damage detected with lis-
samine green were slightly higher after 3-MF
exposure, but this effect was not statistically
significant. The tear-film break-up time was
significantly higher at the end of the 2-hr
exposure period compared with the air control
(Table 1). The observed changes were similar
in subjects with or without atopy.
Nasal measurements. We observed a
washout effect with decreased biomarker con-
centrations after repeated lavages following
exposure to air. In contrast, compared with air
controls, we observed an increase that was
significant for MPO directly after and for
lysozome 2 hr after exposure (Table 2). Nasal
cavity dimensions, measured by acoustic rhi-
nometry, were not different from air control
(Table 3). Stratiﬁcation by atopy did not show
different reactivity for biomarkers or rhino-
metry, although baseline levels of ECP and
albumin were doubled for subjects with atopy.
Airway measurements. On average FVC
decreased 0.1 L directly after exposure to
3-MF, which was a signiﬁcant decrease com-
pared with air control. The other lung function
parameters (transfer test, VC, FEV1, PEF)
were not affected by exposure to 3-MF com-
pared with clean air (Table 4). Stratiﬁcation by
atopy showed that the observed effect on FVC
mainly appeared among nonatopics.
Discussion
Although the exposure level of 3-MF was near
the smell threshold and did not cause subjec-
tive symptoms of mucosal irritation or airway
distress, the objective measurements did show
effects on the eyes and airways. Considering
an increase of the blinking frequency as an
indicator of eye irritation together with the
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Figure 2. Blinking frequency during 2-hr exposures
to 3-MF and air measured as mean frequencies
every 2 min for 29 subjects.
Table 1. Eye measurements (mean ± SD) in 29 subjects exposed to 1 mg/m3 3-MF or clean air for 2 hr.
Measured break-up time (sec) Self-reported break-up time (sec) Blinking frequency Lissamine staining
Exposure Before Aftera 4 hr afterb Before Aftera 4 hr afterb during exposurec after exposured
Air 36 ± 19 –3 ± 17 –3 ± 17 32 ± 19 3 ± 17 3 ± 14 5.8 ± 0.7 0.2 ± 0.3
3-MF 33 ± 21 6 ± 8* –1 ± 16 35 ± 21 2 ± 20 –4 ± 19 7.6 ± 0.8** 0.3 ± 0.5
aEnd of exposure compared with before exposure; negative value indicates decrease. bFour hours after exposure compared with before exposure; negative value indicates decrease. cBlinking
frequency (blinks per minute) during exposure. dEpithelial damage score (0–9), measured by lissamine staining, 4 hr after exposure. *p = 0.014 by Wilcoxon rank sum test. **p < 0.001 by
repeated-measures ANOVA.
Table 2. Nasal biomarkers (mean ± SD) in 29 subjects exposed to 1 mg/m3 3-MF or clean air for 2 hr.
Lysozyme (mg/L) ECP (µg/L) MPO (µg/L) Albumin (mg/L)
Exposure Before Aftera 2 hr afterb Before Aftera 2 hr afterb Before Aftera 2 hr afterb Before Aftera 2 hr afterb
Air 4.5 ± 2.3 –0.6 ± 1.9 0.2 ± 2.4 3.3 ± 4.7 –0.3 ± 3.4 –0.9 ± 3.0 42.2 ± 53.0 –10.2 ± 25.8 –14.2 ± 27.7 17.6 ± 22.4 –6.3 ± 15.2 –4.4 ± 18.0
3-MF 3.8 ± 1.9 0.3 ± 2.0 1.7 ± 3.0* 2.6 ± 4.5 0.4 ± 5.0 –0.3 ± 3.3 34.8 ± 44.2 4.8 ± 44.6* –4.9 ± 27.7 14.1 ± 21.9 –0.4 ± 14.5 1.8 ± 12.1
aEnd of exposure compared with before exposure; negative value indicates decrease. bTwo hours after exposure compared with before exposure; negative value indicates decrease. *p < 0.05
by Wilcoxon rank sum test.
Table 3. Nasal measurements (mean ± SD) in 29 subjects exposed to 1 mg/m3 3-MF or clean air for 2 hr.
Volume (cm3) MCA (cm2) 
Exposure Before Aftera 2 hr afterb Before Aftera 2 hr afterb
Air 9.7 ± 1.7 –1.0 ± 0.8 –0.9 ± 1.2 0.9 ± 0.2 0.0 ± 0.1 0.0 ± 0.2
3-MF 10.0 ± 2.1 –0.8 ± 1.7 –0.8 ± 1.7 0.9 ± 0.2 –0.1 ± 0.1 0.0 ± 0.2
MCA, minimal cross-section area. 
aEnd of exposure compared with before exposure; negative value indicates decrease. bTwo hours after exposure compared with before exposure; negative value indicates decrease.
Table 4. Pulmonary function (mean ± SD) in 29 subjects exposed to 1 mg/m3 3-MF or clean air for 2 hr.
FVC (L) FEV1 (L) PEF (L/min) DLCO (µmol/sec/kPa) 
Exposure Before Aftera 2 hr afterb Before Aftera 2 hr afterb Before Aftera 2 hr afterb Before Afterc
Air 4.8 ± 1.0 0.0 ± 0.2 –0.1 ± 0.2 4.0 ± 0.8 0.0 ± 0.2 –0.1 ± 0.2 510 ± 120 0 ± 30 –20 ± 40 220 ± 60 0 ± 30
3-MF 4.9 ± 1.0 –0.1 ± 0.2* –0.2 ± 0.2 4.0 ± 0.8 –0.1 ± 0.2 –0.2 ± 0.2 500 ± 120 –10 ± 40 –20 ± 40 220 ± 60 10 ± 30
aEnd of exposure compared with before exposure; negative value indicates decrease. bTwo hours after exposure compared with before exposure; negative value indicates decrease.
cTwenty minutes after exposure compared with before exposure.
*p < 0.05 by t-test.nasal biomarker response, it is possible that 3-
MF might have mucosal effects in both the
eyes and the airways. We also found an
increased tear ﬁlm break-up time after expo-
sure to 3-MF. The tear ﬁlm stability is depen-
dent on the quality and amount of the fatty
layer on its surface that is produced from the
meibomian glands. The secretion from these
glands is stimulated by the blinking move-
ments, and a congruent increase of both blink-
ing frequency and break-up time can be
expected.
MPO is a marker of the neutrophil activity
in the nasal mucosa, and lysozyme is a marker
of both neutrophil activity and secretory
neurogenic stimuli. Because nasal lavage was
performed three times, a washout effect with
decreased concentrations could be expected.
We observed this decrease for all lavage bio-
markers after exposure to air in contrast to an
increase after exposure to 3-MF. Also, the
decreased FVC after exposure to 3-MF indi-
cates an airway effect. This pulmonary func-
tion variable is slightly more sensitive to airway
irritation and hyperreactivity than is the VC
measurement with slow expiration.
3-MF is metabolically activated via micro-
somal oxidation, cleaving the furan ring to a
highly reactive unsaturated dialdehyde,
methylbutenedial, that binds covalently to tis-
sue macromolecules (Ravindranath et al.
1984). Animal inhalatory studies have
revealed organ damage at high exposures.
Haschek et al. (1984) reported that rats inhal-
ing 1,000 mg/m3 3-MF for 1 hr had damaged
airway epithelium with pneumonitis and
necrotizing suppurative rhinitis. They also
observed necrosis, fibrosis, and epithelial
metaplasia in the airways at autopsy 14 days
later. Previous epidemiologic results also show
airway reactions related to 3-MF in indoor air
(Smedje et al. 1996).
This suspected adverse reaction was previ-
ously reported (Wålinder et al. 1998) in a sub-
ject with atopy who previously had been
working in a mushroom farm and with micro-
fungi. This subject suffered an acute obstruc-
tive reaction and a delayed pulmonary reaction
with flulike symptoms. A nonspecific airway
reaction could explain the immediate effects
and an infection the late reaction, but no infec-
tion was veriﬁed by laboratory tests. Instead,
analyses afterward showed mold allergy and
high titers of IgE (Wålinder et al. 1998).
Previous exposure to fungi at work could have
resulted in a sensitization causing the present
reaction to 3-MF. Hypersensitivity pneumoni-
tis is an occupational disease from exposure to
organic dust, fungi, or mold. One of the mani-
festations is called mushroom picker’s disease.
The symptoms are similar to those of the pre-
sent reaction but are mostly seen after exposure
to high-molecular-weight organic chemicals.
There are, however, low-molecular-weight
chemicals that can cause immunologic
responses, for example, isocyanates and acid
anhydrides. It is possible that 3-MF after
bioactivation is covalently binding to proteins
of the mucosa, causing both chemical injury
and a protein-hapten reaction resulting in air-
way inflammation and a hypersensitivity
pneumonitis.
Short-term experimental studies differ in
many aspects in relation to real indoor expo-
sures. Indoor exposures involve a high number
of substances, typically at concentrations
10–1,000 times lower than those used in
experimental studies but with possible chemi-
cal interactions. Furthermore, domestic expo-
sures are much longer. Therefore, it has been
suggested that toxic effect estimates of indoor
volatile compounds should be adjusted for
long-term exposures compared with shorter
exposures, at least for nonirritative effects
(Damgård-Nielsen et al. 1997). Using this
argument, it might be justifiable to apply
higher concentrations of indoor agents in
experimental chamber studies. Another impor-
tant issue that must be considered is a differ-
ence in individual susceptibility. A “healthy
volunteer bias” could underestimate the effects
compared with persons who, because of long-
term daily exposures, have acquired a form of
sensitivity to “sick buildings.” Because persons
with atopy are considered more sensitive to
dampness, mold, or other disturbances of the
indoor environment, subjects with IgE-medi-
ated allergy to common allergens were
recruited for the present study. However,
results do not support the statement that per-
sons with atopy report more symptoms or have
a higher reactivity to this fungal metabolite.
Actually, the only difference observed in reac-
tivity was that nonatopics had a decrease in
FVC after exposure to 3-MF, whereas no such
effect was seen among the subjects with atopy.
In conclusion, we have recorded acute
effects from the eyes, nose, and airways indicat-
ing mucosal reactive properties of 3-MF,
which is commonly found in buildings affected
by microbial growth. The mucosal effects
could be induced by a possible chemical injury
from the bioactivation of 3-MF. More unusual
but severe effects, such as hypersensitivity reac-
tions after exposure to fungi and molds, could
also be explained by a protein-hapten reaction.
Therefore, the results of the present study may
have relevance for the judgment of health
problems due to microbial emissions.
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CORRECTION
The 3-min value for 3-MF in Figure 4E was
incorrect in the original manuscript pub-
lished online. The ﬁgure has been corrected
here.